Andrew Allen Net Worth

The estimated Net Worth of Andrew R Allen is at least $9.49 Milhão dollars as of 15 May 2024. Andrew Allen owns over 24,263 units of Gritstone Bio Inc stock worth over $482,826 and over the last 13 years he sold GRTS stock worth over $6,817,990. In addition, he makes $2,187,440 as President, Chief Executive Officer, e Director at Gritstone Bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Allen GRTS stock SEC Form 4 insiders trading

Andrew has made over 6 trades of the Gritstone Bio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 24,263 units of GRTS stock worth $18,197 on 15 May 2024.

The largest trade he's ever made was selling 80,000 units of Gritstone Bio Inc stock on 15 January 2015 worth over $5,251,200. On average, Andrew trades about 5,103 units every 111 days since 2011. As of 15 May 2024 he still owns at least 985,360 units of Gritstone Bio Inc stock.

You can see the complete history of Andrew Allen stock trades at the bottom of the page.

Andrew Allen biography

Dr. Andrew R. Allen M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Allen co-founded Gritstone Oncology, Inc. and has served as our President and Chief Executive Officer and a member of our board of directors since September 2015. Prior to Gritstone, in April 2009, Dr. Allen co-founded Clovis Oncology, Inc., a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme, Inc., a publicly traded biopharmaceutical company, Sierra Oncology, Inc., a publicly traded biopharmaceutical company, TCR2 Therapeutics Inc, a publicly traded biopharmaceutical company, and Revitope Inc., a privately-held biotechnology company. Dr. Allen previously served on the board of directors of Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London. Allen is qualified to serve on our board of directors due to his educational experience and his experience as a senior executive of biotechnology and pharmaceutical companies, including his service as our chief executive officer.

What is the salary of Andrew Allen?

As the President, Chief Executive Officer, e Director of Gritstone Bio Inc, the total compensation of Andrew Allen at Gritstone Bio Inc is $2,187,440. There are no executives at Gritstone Bio Inc getting paid more.

How old is Andrew Allen?

Andrew Allen is 53, he's been the President, Chief Executive Officer, e Director of Gritstone Bio Inc since 2015. There are 7 older and 12 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..

What's Andrew Allen's mailing address?

Andrew's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.

Insiders trading at Gritstone Bio Inc

Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson, eThomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.

What does Gritstone Bio Inc do?

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Complete history of Andrew Allen stock trades at Adaptimmune Therapeutics Plc, Clovis Oncology Inc, Epizyme Inc, Sierra Oncology Inc, Gritstone Bio Inc, eTCR2 Therapeutics

Gritstone Bio Inc executives and stock owners

Gritstone Bio Inc executives and other stock owners filed with the SEC include:

• Andrew Allen,
  President, Chief Executive Officer, Director
• Jean-Marc Bellemin,
  Chief Financial Officer, Executive Vice President
• Raphael Rousseau,
  Executive Vice President, Chief Medical Officer
• Karin Jooss,
  Executive Vice President - Research, Chief Scientific Officer
• Roman Yelensky,
  Executive Vice President, Chief Technology Officer
• Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.,
  Co-Founder, Pres, CEO & Director
• Erin E. Jones M.S.,
  Chief Operating Officer
• Steve Krognes,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Richard Heyman,
  Independent Director
• Judith Li,
  Independent Director
• Nicholas Simon,
  Independent Director
• Elaine Jones,
  Chairman of the Board
• Vijay Yabannavar,
  Executive Vice President, Manufacturing and Technical Operations
• Erin Jones,
  Executive Vice President, Global Head of Regulatory Affairs and Quality Assurance
• Matthew Hawryluk,
  Executive Vice President, Chief Business Officer
• Alan C. Mendelson J.D.,
  Sec.
• Dr. Karin Jooss,
  Head of R&D
• Dr. Matthew Hawryluk,
  Exec. VP & Chief Bus. Officer
• Prof. Raphael F. Rousseau M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Stacy Proctor,
  Sr. VP & Head of People
• Rahsaan W. Thompson J.D.,
  Exec. VP & Gen. Counsel
• James Cho,
  Chief Accounting Officer
• Vassiliki Economides,
  Exec. VP & CFO
• Stephen W Webster,
  
• Group, Llc Green Jeremy Red...,
  
• Venture Capital V, L.P.Vers...,
  
• Peter Svennilson,
  Director
• Group Ii, Lp Column Group I...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Rahsaan Thompson,
  EVP and General Counsel
• Shefali Agarwal,
  
• Clare Fisher,
  
• Naiyer Rizvi,
  
• Lawrence Corey,
  
• James Cho,
  SVP, CHIEF ACCOUNTING OFFICER
• Vassiliki Economides,
  EVP, CHIEF FINANCIAL OFFICER